ClinicalTrials.gg
Status unknownNCT04866485Updated Apr 29, 2021

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

A Phase 1 interventional study of HBM4003 and pembrolizumab in Solid Tumor, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-29.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.

Read the detailed description

subjects will be treated with HBM4003 in combination with pembrolizumab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first.

This trial consists of :

  • A screening period: 28 days
  • A treatment period:

    • Part 1a dose confirmation study
    • Part 1b dose expansion study
  • A post-treatment follow-up period, including

    • A safety follow-up period: 28 days after the last dose of study drug;
    • Post-treatment follow-up visit: day 84 after the last dose of study drug;
    • Survival follow-up.
02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Harbour BioMed (Guangzhou) Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years old at the time of signing the and ≤ 75 years old at the time of enrollment.
  • Patients for Part 1a: patients diagnosed with advanced or recurrent solid tumors.
  • Patients for Part 1b: patients diagnosed with NSCLC and confirmed with negative tumor expression (TPS\<1%).
  • Patients for Part 1b dose expansion study: have never received systemic therapies as primary therapy for advanced or metastatic diseases.
  • Patients must be able to provide fresh tumor tissues or archived tumor tissues.
  • Patients whose estimated survival time is more than 3 months.
  • Patients with at least one at baseline according to (version 1.1).
  • Patients with (ECOG) performance status score ≤ 1.
  • Patients whose organ function must meet the study requirements.
  • Males or females with need to use an effective method.
  • Willing and able to comply with study-specified visits schedule, treatment plan, laboratory examination and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • NSCLC patients with EGFR-sensitive mutations or an ALK translocation based on diagnosis results.
  • Patients who are simultaneously participating in another clinical study, unless the study is an observational (non-interventional) clinical study or the patient is already in the survival follow-up period of the interventional study.
  • Patients with a medical history of severe allergic diseases, a history of severe drug allergies, and are known or suspected allergy to macromolecular protein preparations or HBM4003 or pembrolizumab .
  • Previous and concomitant drugs or treatments to be excluded like CTLA4, ,PD-L1.
  • Insufficient completely recovery from previous treatments.
  • Diseases that may affect the efficacy and safety of the product.
  • A history of other malignant diseases within 5 years before the first dose.
  • Active or during screening or previous with imaging evidence (based on CT or MRI assessment).
  • Patients who have received palliative radiotherapy for non-central nervous system lesions within 2 weeks before the first dose.
  • Patients who have received more than 30 Gy of lung radiation therapy within 6 months before the first dose.
  • A history of interstitial lung disease or non-infectious pneumonia.
  • Patients with pleural effusion, pericardial effusion, or ascites.
  • Patients that may have other conditions that affect the efficacy or safety evaluation of this study (such as mental disorder, alcoholism, drug abuse, etc.) .
  • Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period and within 3 months after the last dose of study drug.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    HBM4003+pembrolizumab

    HBM4003 combined with pembrolizumab in subjects with advanced NSCLC and other solid tumors

    Drug: HBM4003 and pembrolizumab

Interventions

  • DrugHBM4003 and pembrolizumab

    Drug pages: Porustobart · Pembrolizumab

    Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.

    Also known as: HBM4003

06

What researchers measure

Primary outcomes

  1. Part 1a: Number of subjects with DLT in each dose group within 1 cycles (21 days) after the first drug administration

    DLT observation period was defined as one treatment cycles with a total of 21 days

    Time frame: approximate 21 days

  2. Part 1b: ORR

    Proportion of subjects with complete response (CR) and partial response (PR)

    Time frame: maximum 2 years

Secondary outcomes

  1. Part 1a: ORR

    including proportions of subjects with complete response (CR) and partial response (PR)

    Time frame: maximum 2 years

  2. Part 1a: Disease Control Rate, DCR

    including proportion of subjects with complete response (CR) and partial response (PR) and stable disease (SD)

    Time frame: maximum 2 years

  3. Part 1a: Duration of Response, DOR

    Calculate the duration from the first confirmed CR or PR to the date of disease progression or death (for any reason)

    Time frame: maximum 2 years

  4. Part 1a: Duration of Disease Control, DDC

    For subjects with Cr, PR or SD, the duration from the time of initial administration to the date of disease progression or death (for any reason) was calculated

    Time frame: maximum 2 years

  5. Cmax

    Peak Plasma Concentration

    Time frame: maximum 2 years

  6. Tmax

    Time to reach maximum serum concentration

    Time frame: maximum 2 years

  7. AUC0-last

    Area under the plasma concentration versus time curve from time zero to last

    Time frame: maximum 2 years

  8. AUC0-tau

    Area under the serum concentration versus time curve from time zero to the dosing interval tau

    Time frame: maximum 2 years

  9. UC0-inf

    Area under the serum concentration versus time curve from time zero to infinity

    Time frame: maximum 2 years

  10. Vss

    Volume of distribution at steady state

    Time frame: maximum 2 years

  11. CL

    Clearance

    Time frame: maximum 2 years

  12. t1/2

    Terminal half-life

    Time frame: maximum 2 years

  13. Part 1a: Immunogenicity of HBM4003 and pembrolizumab

    including the occurrence of positive anti-drug antibodies (ADA). The occurrence of neutralizing antibodies for subjects with positive ADA

    Time frame: maximum 2 years

  14. Part 1b: Number of subjects experiencing at least one treatment-related AE

    Evaluate safety

    Time frame: maximum 2 years

  15. Part 1b: DCR

    including proportion of subjects with CR, PR and SD

    Time frame: maximum 2 years

  16. Part 1b: DOR

    calculate the duration from the first confirmed CR or PR to the date of disease progression or (for any reason) death.

    Time frame: maximum 2 years

  17. Part 1b: DDC

    for subjects with CR, PR or SD, calculate the duration from the time of initial medication to the day of disease progression or (for any reason) death

    Time frame: maximum 2 years

  18. Part 1b: Overall survival (OS)

    the length of time from the start of treatment to the death of the subject (for any reason)

    Time frame: maximum 2 years

  19. Part 1b: Progression-free survival (PFS)

    the length of time from the beginning of treatment to the beginning of disease progression or death (for any reason)

    Time frame: maximum 2 years

  20. Part 1b: Immunogenicity of HBM4003 and pembrolizumab

    including the occurrence of positive anti-drug antibodies (ADA). The occurrence of neutralizing antibodies for subjects with positive ADA.

    Time frame: maximum 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2021; primary completion for Feb 2023, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
Apr 29, 2021
StartEst.
Jun 14, 2021
Primary completionEst.
Feb 2023
CompletionEst.
Feb 2023
Last update
Apr 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04866485
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Jun 14, 2021 (estimated)
Primary completion
Feb 2023 (estimated)
Completion
Feb 2023 (estimated)
Last update
Apr 29, 2021

Study contacts

Xi LIU
Contact
hbm4003public@harbourbiomed.com
+8618616529165
Peter ZHAO
Contact
hbm4003public@harbourbiomed.com
+8617601647910
Shun LU, Doctor
principal investigator · Shanghai Chest Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Porustobart · Pembrolizumab

Start the discussion